LAB — Labiana Health SA Income Statement
0.000.00%
Last trade - 00:00
- €17.79m
- €33.25m
- €58.46m
- 43
- 40
- 80
- 55
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 48.4 | 57.8 | 57 | 57.8 | 58.5 |
Cost of Revenue | |||||
Gross Profit | 29.4 | 34.1 | 35.4 | 32.5 | 34.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 46.4 | 55.4 | 56.4 | 64.1 | 60.5 |
Operating Profit | 1.97 | 2.46 | 0.54 | -6.23 | -2.06 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.762 | 0.541 | -2.12 | -7.84 | -5.27 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.879 | 1.07 | -2.11 | -9.11 | -4.49 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 0.656 | 1.07 | -1.78 | -8.94 | -4.42 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.656 | 1.07 | -1.78 | -8.94 | -4.42 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.048 | 0.162 | -0.182 | -0.875 | -0.583 |